CF
HRTX icon

Corebridge Financial’s Heron Therapeutics HRTX Stock Holding History

Corebridge Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-57,515
Closed -$127K – 1253
2025
Q1 		$127K Sell
57,515
-852
-1% -$1.65K ﹤0.01% 2319
2024
Q4 		$89.3K Sell
58,367
-4,406
-7% -$7.14K ﹤0.01% 2600
2024
Q3 		$125K Sell
62,773
-386
-0.6% -$922 ﹤0.01% 2486
2024
Q2 		$221K Buy
+63,159
New +$194K ﹤0.01% 2133

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Corebridge Financial's HRTX Position: Q2 2025 in Review

Corebridge Financial sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 57,515 shares — an estimated $127K sold.

Corebridge Financial first reported a position in HRTX in Q2 2024 and held it in 4 quarters. The position peaked at $221K in Q2 2024. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

  • Corebridge Financial reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 57,515 Heron Therapeutics shares in Q2 2025, an estimated $127K.
  • Corebridge Financial first reported a position in Heron Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Heron Therapeutics position peaked at $221K in Q2 2024.
  • 171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.